Mechanisms of altered sensitivity to endothelin-1 between aortic smooth muscles of spontaneously hypertensive and Wistar-Kyoto rats. 1991

Y Tomobe, and T Ishikawa, and M Yanagisawa, and S Kimura, and T Masaki, and K Goto
Department of Pharmacology, University of Tsukuba, Ibaraki, Japan.

Endothelin-1 (ET-1) caused a dose-dependent vasoconstriction in rat aortic strips in vitro. The sensitivity to ET-1 was significantly higher in 12-week-old spontaneously hypertensive rats (SHR) than in age-matched Wistar-Kyoto (WKY) rats. In contrast, the sensitivity was not different between SHR and WKY rats at 6 weeks of age, which was close to that of 12-week-old SHR. Receptor binding study in microsomal preparations of the aortas with [125I]ET-1 showed that maximum binding value for ET-1 receptor in 12-week-old SHR was only 1.5-fold greater than that in WKY rats and that there was no significant difference in the Kd values. K(+)-depolarization induced vasoconstrictive responses that were also augmented in 12-week-old SHR. Resting membrane potential of the aorta was significantly depolarized in tissues from 12-week-old SHR compared with age-matched WKY rats. The resting membrane potentials were similar in the aorta from 6-week-old SHR and WKY rats, and were between those of 12-week-old SHR and WKY rats. When the aortic strips from 12-week-old WKY rats were partially depolarized in high K(+)-solution or in the presence of ouabain (0.1 mM), the vasoconstrictor effect of ET-1 became similar to that on the strips from SHR in a normal solution. These results suggest that, although age-dependent changes appear to be complicated, the lower resting membrane potential may account considerably for the larger sensitivity to ET-1 in the aorta from 12-week-old SHR than that from age-matched WKY rats.

UI MeSH Term Description Entries
D008297 Male Males
D008564 Membrane Potentials The voltage differences across a membrane. For cellular membranes they are computed by subtracting the voltage measured outside the membrane from the voltage measured inside the membrane. They result from differences of inside versus outside concentration of potassium, sodium, chloride, and other ions across cells' or ORGANELLES membranes. For excitable cells, the resting membrane potentials range between -30 and -100 millivolts. Physical, chemical, or electrical stimuli can make a membrane potential more negative (hyperpolarization), or less negative (depolarization). Resting Potentials,Transmembrane Potentials,Delta Psi,Resting Membrane Potential,Transmembrane Electrical Potential Difference,Transmembrane Potential Difference,Difference, Transmembrane Potential,Differences, Transmembrane Potential,Membrane Potential,Membrane Potential, Resting,Membrane Potentials, Resting,Potential Difference, Transmembrane,Potential Differences, Transmembrane,Potential, Membrane,Potential, Resting,Potential, Transmembrane,Potentials, Membrane,Potentials, Resting,Potentials, Transmembrane,Resting Membrane Potentials,Resting Potential,Transmembrane Potential,Transmembrane Potential Differences
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D010042 Ouabain A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE. Acocantherin,G-Strophanthin,Acolongifloroside K,G Strophanthin
D011188 Potassium An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
D011918 Rats, Inbred SHR A strain of Rattus norvegicus with elevated blood pressure used as a model for studying hypertension and stroke. Rats, Spontaneously Hypertensive,Rats, SHR,Inbred SHR Rat,Inbred SHR Rats,Rat, Inbred SHR,Rat, SHR,Rat, Spontaneously Hypertensive,SHR Rat,SHR Rat, Inbred,SHR Rats,SHR Rats, Inbred,Spontaneously Hypertensive Rat,Spontaneously Hypertensive Rats
D011921 Rats, Inbred WKY A strain of Rattus norvegicus used as a normotensive control for the spontaneous hypertensive rats (SHR). Rats, Wistar Kyoto,Wistar Kyoto Rat,Rats, WKY,Inbred WKY Rat,Inbred WKY Rats,Kyoto Rat, Wistar,Rat, Inbred WKY,Rat, WKY,Rat, Wistar Kyoto,WKY Rat,WKY Rat, Inbred,WKY Rats,WKY Rats, Inbred,Wistar Kyoto Rats
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response

Related Publications

Y Tomobe, and T Ishikawa, and M Yanagisawa, and S Kimura, and T Masaki, and K Goto
May 1990, British journal of pharmacology,
Y Tomobe, and T Ishikawa, and M Yanagisawa, and S Kimura, and T Masaki, and K Goto
January 1989, Life sciences,
Y Tomobe, and T Ishikawa, and M Yanagisawa, and S Kimura, and T Masaki, and K Goto
January 1987, Clinical and experimental hypertension. Part A, Theory and practice,
Y Tomobe, and T Ishikawa, and M Yanagisawa, and S Kimura, and T Masaki, and K Goto
January 1987, Alcohol and drug research,
Y Tomobe, and T Ishikawa, and M Yanagisawa, and S Kimura, and T Masaki, and K Goto
October 1996, The American journal of physiology,
Y Tomobe, and T Ishikawa, and M Yanagisawa, and S Kimura, and T Masaki, and K Goto
January 1990, General pharmacology,
Y Tomobe, and T Ishikawa, and M Yanagisawa, and S Kimura, and T Masaki, and K Goto
August 1988, European journal of pharmacology,
Y Tomobe, and T Ishikawa, and M Yanagisawa, and S Kimura, and T Masaki, and K Goto
January 1980, Clinical and experimental hypertension,
Y Tomobe, and T Ishikawa, and M Yanagisawa, and S Kimura, and T Masaki, and K Goto
March 1990, Regulatory peptides,
Copied contents to your clipboard!